Partisan Gridlock on Healthcare Costs Continues

Emerging Compromise on Pharmacy Benefit Manager Reform

Republicans and Democrats in Congress are still facing significant partisan gridlock regarding strategies to lower healthcare costs. However, a potential area of compromise surfaced during a contentious Senate Finance Committee hearing on Wednesday, focusing on pharmacy benefit manager (PBM) reform. Senate Finance Chair Mike Crapo, R-Idaho, and Ranking Member Ron Wyden, D-Ore., announced plans to reintroduce a bipartisan package aimed at regulating PBMs, who act as middlemen in the drug supply chain.

Background on Previous Legislative Efforts

This legislation nearly advanced through Congress late last year as part of a broader appropriations bill but ultimately failed due to public opposition from billionaire Elon Musk, an influential ally of former President Donald Trump. Crapo indicated that the PBM legislation would be reintroduced “shortly,” with hopes of expediting its passage to the president’s desk.

The Role and Influence of PBMs

Understanding Pharmacy Benefit Managers

Pharmacy benefit managers serve as intermediaries between drug manufacturers, payers, and pharmacies, holding substantial power over the medications patients receive and their associated costs. As a result, they have become a focal point for legislators and regulators in Washington who seek to make medications more affordable.

Focus on Major PBMs

Particular attention has been directed toward the “Big Three” PBMs—Express Scripts, CVS Caremark, and Optum Rx—which collectively manage approximately 80% of U.S. prescriptions and are owned by major insurance companies. Pharmaceutical companies, independent pharmacies, and certain health policy experts argue that vertical consolidation encourages PBMs to inflate medication costs and direct patients to their own pharmacies. In contrast, PBMs assert that they are uniquely positioned to negotiate lower prices, demonstrating value to employers and payers through savings derived from drug manufacturers.

Bipartisan Support and Legislative Proposals

Past Legislative Attempts

Despite the opposition, there is considerable bipartisan support in Congress for curbing PBMs, leading to various proposals over recent years, including complete disbandment of PBM conglomerates. Last December, Congress nearly passed a set of moderate reforms as part of an annual appropriations bill, but the PBM provisions were removed following criticism from Musk.

Current Legislative Developments

The Senate Finance Committee is now revisiting the PBM reform package, which could potentially be included in appropriations legislation by the year’s end or early next year. Congress must pass new funding legislation by January 30. Crapo emphasized that PBM reform would “realign incentives in the drug supply chain to lower patient costs at the pharmacy counter.”

Key Components of the Proposed Legislation

The original reform package aims to decouple PBM compensation from drug prices by mandating that Medicare’s Part D prescription drug plans pay PBMs a flat fee, rather than allowing them to retain a portion of the negotiated drug savings. Additionally, PBMs would be required to pass through 100% of the rebates from drug manufacturers to Part D sponsors. The proposal would also eliminate the controversial practice of spread pricing in Medicaid, where PBMs charge plans a higher price for drugs than what pharmacies are paid. Furthermore, PBMs would need to provide detailed data on prescription drug spending to federal regulators and their clients.

Uncertain Outcomes and Broader Healthcare Challenges

Reactions from Stakeholders

These policies have garnered broad support from pharmacist groups, patient advocates, and lawmakers. However, there is uncertainty regarding whether such reforms will effectively reduce patient costs. The Pharmaceutical Care Management Association, the primary lobby for the PBM industry, did not respond to inquiries about the potential reintroduction of the package.

Challenges in Addressing Cost Increases

Despite identifying a potential route for PBM reform, lawmakers are still struggling to protect Americans from significant cost increases in the Affordable Care Act exchanges, which are set to take effect on January 1. Experts in health policy suggest that the only viable solution Congress could implement in time is a straightforward extension of more generous subsidies for coverage, a measure supported by Democrats. However, such an extension appears increasingly unlikely given the strong opposition from Trump and his supporters.